Article Abstract

First-line immunotherapy for patients with advanced stage or metastatic non-small cell lung cancer…finally what threshold of PD-L1 expression on tumor cells?

Authors: Paul Hofman

Abstract

A certain number of patients with advanced stage or metastatic non-small cell lung cancer (NSCLC) show better overall survival when treated with first-line immunotherapy than patients treated with chemotherapy (1). This finding, originally reported in KEYNOTE-024, has just been updated and continues to confirm, for the same cohort of patients, benefit from first-line pembrolizumab treatment (1,2).

Article Options

Download Citation